As China Dives Into RWE, J&J Teams Up To Tackle Depression

A new tie-up between J&J and a Singapore startup portends a new chapter for China drug development, using real world data and associated evidence, as China moves to clarify RWE regulations.

Neuroscience development and training concept as a group of cog wheels and gears shaped as human head with information transfer as a technology brain symbol or psychology exchange as a 3D render. - Illustration
China Drafts RWE Reg As J&J Enters Digital Health Alliance For Depression • Source: Shutterstock

An estimated 54 million people suffer from depression in China and the figure is rising. Despite accounting for around 4% of the total population, many sufferers are still not properly diagnosed and/or treated due to a chronic shortage of psychiatrists, while there are only 1.7 physicians per 100,000 people specialized in psychiatric conditions.

Now, one major foreign pharma company is looking to use real world evidence (RWE) to help tackle the issue.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia